Companies › Rein Therapeutics
1 active drug program in 1 registered trial: 1 Phase 2; Respiratory; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LTI-03 Caveolin-1-scaffolding-protein-derived peptide | CAV1 | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF) | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06968845 | LTI-03 | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF) | Respiratory | Sep 2027 |
Cash and short-term investments of $44m on 2026-06-30; operating cash outflow about $24m a year; runway about 21 months at that burn, to Apr 2028; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
–
aTyr Pharma Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA Aimmune Nestlé Health Science US R&D Vicore Pharma SpliSense
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.